ANI Expects Growth From Launches And Novitium Integration
As Company Expects Cortrophin Gel To Have Commercial Longevity
ANI Pharma has outlined key pillars of its strategy to drive growth in the coming quarters as the company reported a slight increase in revenues in the fourth quarter of 2021. The company’s recent purified Cortrophin Gel launch is off to a good start, as ANI leadership counts on its commercial longevity.
You may also be interested in...
Successful Cortrophin Gel Launch Could Drive Growth At ANI For Years To Come
The launch of ANI Pharmaceutical’s Cortrophin gel has reignited interest in the ACTH drug category, and appears set to drive growth at the company for the foreseeable future.
Who’s Hired? Neuraxpharm, Lupin And ANI Announce Appointments
Neuraxpharm, Lupin and ANI have announced changes within their leadership teams, while board members have joined industry associations Medicines for Europe and Australia’s GBMA.
Kelix Strikes A Deal To Acquire 14 Oncology Injectables
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.